(7)　手続における交渉の有無　無。
(8)　その他　詳細は、入札説明書による。なお、入札説明書等で当該調達に関する環境上の条件を定めた調達であると示されている場合は、十分理解した上で応札すること。
5　Summary
(1)　Official in charge of disbursement of the procuring entity : Tatsuo Ushiki, President, National University Corporation Niigata University
(2)　Classification of the products to be procured : 4
(3)　Nature and quantity of the products to be purchased :
A　Bictegravir sodium Emtricitabine Tenofovir alafenamide fumarate (30tablets／vial) 420vials
B　Letermovir (240mg 14tablets／case) 300 cases
C　Olaparib (100mg 56tablets／case) 140 cases
D　Olaparib (150mg 56tablets／case) 420 cases
E　Aflibercept (Genetical Recombination) (2mg 0.05mL／syringe) 480syringes
F　Vutrisiran Sodium Kit (25mg 0.5mL／syringe) 4syringes
G　Tocilizumab (Genetical Recombination) (200mg 10mL／vial) 1,320vials
H　Tocilizumab (Genetical Recombination) (162mg 0.9mL／kit) 1,080cases
I　Paclitaxel (100mg／vial) 1,300vials
J　Cetuximab (Genetical Recombination) (100mg 20mL／vial) 1,350vials
K　Bevacizumab (Genetical Recombination) (100mg 4mL／vial) 870vials
L　Bevacizumab (Genetical Recombination) (400mg 16mL／vial) 1,100vials
M　Durvalumab (Genetical Recombination) (120mg 2.4mL／vial) 460vials
N　Durvalumab (Genetical Recombination) (500mg 10mL／vial) 450vials
O　Canakinumab (Genetical Recombination) (150mg 1mL／vial) 30vials
P　Nivolumab (Genetical Recombination) (100mg 10mL／vial) 210vials
Q　Abatacept (Genetical Recombination) (250mg／vial) 500vials
R　Nivolumab (Genetical Recombination) (240mg 24mL／vial) 970vials
S　Trastuzumab emtansine (Genetical Recombination) (100mg／vial) 120vials
T　Pembrolizumab (Genetical Recombination) (100mg 4mL／vial) 2,530vials
U　Patisiran Sodium (8.8mg 4.4mL／vial) 30vials
V　Burosumab (Genetical Recombination) (30mg 1mL／vial) 30vials
W Freeze-dried polyethylene glycol treated human normal immunoglobulin (5g 100mL／vial (with soluation)) 900vials
X　Polyethylene glycol treated human normal immunoglobulin (10g 100mL／vial) 860vials
Y　Tisagenlecleucel 3sets
Z　Ramucirumab (Genetical Recombination) (500mg 50mL／vial) 110vials
AA　Palivizumab (Genetical Recombination) (100mg 1mL／vial) 480vials
AB　Ustekinumab (Genetical Recombination) (45mg 0.5mL／syringe) 560syringes
AC　Asfotase alfa (Genetical Recombination) (28mg 0.7mL／vial) 120vials
AD　Asfotase alfa (Genetical Recombination) (80mg 0.8mL／vial) 390vials
AE　Pegfilgrastim (Genetical Recombination) (3.6mg 0.36mL／syringe) 670syringes
AF　Nusinersen Sodium (12mg 5mL／vial) 6vials
AG　Imiglucerase (Genetical Recombination) (400units／vial) 150vials
AH　Lanreotide Acetate (120mg／syringe) 130syringes
AI　Daratumumab (Genetical Recombination) (400mg 20mL／vial) 200vials
AJ　Atezolizumab (Genetical Recombination) (1,200mg 20mL／vial) 420vials
AK　Mepolizumab (Genetical Recombination) (100mg 1mL／kit) 390kits
AL　Pertuzumab (Genetical Recombination) (420mg 14mL／vial) 220vials
AM　Avelumab (Genetical Recombination) (200mg 10mL／vial) 290vials
AN　Blinatumomab (Genetical Recombination) (35μg／vial (with infusion stabilization liquid)) 200vials
AO　Adalimumab (Genetical Recombination) (40mg 0.4mL／syringe) 470syringes
AP　Benralizumab (Genetical Recombination) (30mg 1mL／syringe) 100syringes
AQ　Sugammadex Sodium (200mg 10mL 10vials／case) 330case s
AR　Remdesivir (100mg／vial) 420vials
AS　Ipilimumab (Genetical Recombination) (50mg 10mL／vial) 70vials
AT　Ravulizumab (Genetical Recombination) (300mg 3mL／vial) 650vials
AU　Dinutuximab (Genetical Recombination) (17.5mg 5mL／vial) 60vials
AV　Denosumab (Genetical Recombination) (120mg 1.7mL／vial) 1,080vials
AW　Elapegademase (Genetical Recombination) (2.4mg 1.5mL／vial) 50vials
AX　Infliximab (Genetical Recombination) (100mg／vial) 1,590vials
AY　Romiplostim (Genetical Recombination) (250μg／vial) 1,240vials
(4)　Delivery period : From 1 April, 2024 through 31 March, 2025
(5)　Delivery place : Niigata University Medical and Dental Hospital
(6)　Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A　not come under Article 4 over the past one year and Article 3 of the Regulation concerning the Contract for Niigata University Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,
B　have the Grade A or Grade B qualification during fiscal 2023 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency,
C　prove to have obtained license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,
D　prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by the President, National University Corporation Niigata University,
E　meet the qualification requirements which President, National University Corporation Niigata University may specify in accordance with Article 5 of the Regulation,
F　not be currently under a suspension of business order as instructed by President, National University Corporation Niigata University.
(7)　Time limit of tender : 17 : 15　14 March, 2024
(8)　Contact point for the notice : Hiromasa Kawada, Procurement Section, Niigata University Medical and Dental Hospital, 754 Asahimachidori 1-bancho Chuo-ku Niigata-shi 951―8520 Japan, TEL 025―227―2430
(9)　Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.

入札公告

次のとおり一般競争入札に付します。
令和６年１月22日
分任契約責任者
国立大学法人富山大学
財務施設部長　溝口　寛士